Department of Pathology, University of Western Ontario, Schulich School of Medicine, London, Ontario, Canada.
Am J Physiol Endocrinol Metab. 2010 Jan;298(1):E127-37. doi: 10.1152/ajpendo.00432.2009. Epub 2009 Nov 10.
Sustained hyperglycemia in diabetes causes alteration of a large number of transcription factors and mRNA transcripts, leading to tissue damage. We investigated whether p300, a transcriptional coactivator with histone acetyl transferase activity, regulates glucose-induced activation of transcription factors and subsequent upregulation of vasoactive factors and extracellular matrix (ECM) proteins in human umbilical vein endothelial cells (HUVECs). HUVECs were incubated in varied glucose concentrations and were studied after p300 small interfering RNA (siRNA) transfection, p300 overexpression, or incubation with the p300 inhibitor curcumin. Histone H2AX phosphorylation and lysine acetylation were examined for oxidative DNA damage and p300 activation. Screening for transcription factors was performed with the Luminex system. Alterations of selected transcription factors were validated. mRNA expression of p300, endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), and fibronectin (FN) and its splice variant EDB(+)FN and FN protein production were analyzed. HUVECs in 25 mmol/l glucose showed increased p300 production accompanied by increased binding of p300 to ET-1 and FN promoters, augmented histone acetylation, H2AX phosphorylation, activation of multiple transcription factors, and increased mRNA expression of vasoactive factors and ECM proteins. p300 overexpression showed a glucose-like effect on the mRNA expression of ET-1, VEGF, and FN. Furthermore, siRNA-mediated p300 blockade or chemical inhibitor of p300 prevented such glucose-induced changes. Similar mRNA upregulation was also seen in the organ culture of vascular tissues, which was prevented by p300 siRNA transfection. Data from these studies suggest that glucose-induced p300 upregulation is an important upstream epigenetic mechanism regulating gene expression of vasoactive factors and ECM proteins in endothelial cells and is a potential therapeutic target for diabetic complications.
糖尿病患者的持续性高血糖会导致大量转录因子和 mRNA 转录本发生改变,从而导致组织损伤。我们研究了转录共激活因子 p300 是否通过调节葡萄糖诱导的转录因子激活以及随后调节血管活性因子和细胞外基质 (ECM) 蛋白在人脐静脉内皮细胞 (HUVEC) 中的表达。将 HUVEC 在不同浓度的葡萄糖中孵育,并在 p300 小干扰 RNA (siRNA) 转染、p300 过表达或用 p300 抑制剂姜黄素孵育后进行研究。通过检测组蛋白 H2AX 磷酸化和赖氨酸乙酰化来检测氧化 DNA 损伤和 p300 激活。通过 Luminex 系统筛选转录因子。验证了选定转录因子的变化。分析了 p300、内皮素-1 (ET-1)、血管内皮生长因子 (VEGF) 和纤维连接蛋白 (FN) 及其剪接变体 EDB(+)FN 的 mRNA 表达以及 FN 蛋白的产生。在 25mmol/L 葡萄糖中,HUVEC 中 p300 的产生增加,同时 p300 与 ET-1 和 FN 启动子的结合增加,组蛋白乙酰化、H2AX 磷酸化、多种转录因子激活以及血管活性因子和 ECM 蛋白的 mRNA 表达增加。p300 过表达对 ET-1、VEGF 和 FN 的 mRNA 表达表现出类似葡萄糖的作用。此外,siRNA 介导的 p300 阻断或 p300 的化学抑制剂可防止这种葡萄糖诱导的变化。在血管组织的器官培养中也观察到了类似的 mRNA 上调,这种上调可通过 p300 siRNA 转染来预防。这些研究结果表明,葡萄糖诱导的 p300 上调是调节内皮细胞中血管活性因子和 ECM 蛋白基因表达的重要上游表观遗传机制,可能是糖尿病并发症的潜在治疗靶点。